Nivolumab,Oxaliplatin,Capecitabine,gimeracil,oteracil,tegafur
ono pharma,BMS,nordic group,otsuka
['nivolumab', 'nivo', 'gicsm', 'gastric', '#gi']
adding nivolumab to adjuvant chemotherapy did not improve relapse-free survival in a phase 3 trial of patients with gastric/gej cancer. #asco23 #gicsm 
https://t.co/bi63MIVP5D is a resource offering oncology health care professionals practical information about the changing clinical landscape.